

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

Andreas Tiede,¹ Faraizah Abdul Karim,² Victor Jiménez-Yuste,³
Robert Klamroth,⁴ Sandra Lejniece,⁵ Takashi Suzuki,⁶ Andreas Groth⁷ and Elena Santagostino⁸

¹Hannover Medical School (MHH), Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany;

²Haemophilia Centre, National Blood Centre, Kuala Lumpur, Malaysia; ³Hospital Universitario La Paz, Autónoma University, Madrid, Spain; ⁴Haemophiliezentrum, Klinik für Innere Medizin, Vivantes Klinikum im Friedrichshain, Berlin, Germany; ⁵Rīga East Clinical University Hospital, Chemotherapy and Hematology Clinic, Rīga, Latvia; ⁶Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan; ⁷Novo Nordisk A/S, Søborg, Denmark and ⁸Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Foundation, Maggiore Hospital Policlinic, Milan, Italy

©2021 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.241554

Received: November 27, 2019.


Accepted: April 22, 2020.

Pre-published: April 23, 2020.

Correspondence: *ANDREAS TIEDE* - tiede.andreas@mh-hannover.de

Supplementary Figure 1. Negative binomial estimates of ABR (mean and 95% CI) for five FVIII:C categories (0-1%, >1-5%, >5-20%, >20-50%, and >50%) for spontaneous joint bleeds during pivotal (A) and extension (B) phases for adults/adolescents, and during pivotal (C) and extension (D) phases for children.

ABR, annualized bleeding rate; CI: confidence interval; FVIII:C: FVIII concentration.



Supplementary Figure 2. Kaplan-Meier estimates of the proportion of patients without a spontaneous joint bleed according to predicted FVIII:C during the pivotal and extension trial phases.

FVIII:C: FVIII concentration.

